Trial Information

Summary: A Phase II Study of Weekly Taxol and Estramustine for Treatment of Prostate Cancer Micrometastases after Radical Prostatectomy or Salvage Radiation Therapy

This research study will evaluate whether there is benefit to treating individuals with chemotherapy for a rising Prostate Specific Antigen(PSA) as the only sign of recurrent prostate cancer after a radical prostatectomy. If the treatment works, it may provide a cure or prolong life or improve the quality of life. There is no guarantee of benefit with participation in this study. The medications used are Taxol weekly for six weeks for two cycles and estramustine taken as a pill by mouth for 3 days every week for six weeks for two cycles. There is no financial compensation for participation in this research study.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

Patients who have had a radical prostatectomy for prostate cancer and meet one of the following PSA criteria:
1)After initial treatment do not reach an undetectable level of PSA;
2) PSA rises at least 2, but no more than 15 ng/dl;
3) PSA rises to 0.2 ng/dl may be eligible. Please call or e-mail contact person listed below for further information.

1. Pathologist finds prostate cancer in the lymph nodes at the time of the prostatectomy;
2. PSA rises greater than 15 ng/dl;
3. Spread of prostate cancer outside the area of the prostate, (for example, to the bone)seen on bone scan or CAT scan;
4. Hormonal therapy for prostate cancer within the past 2 years;
5. History of forming blood clots or blood clotting problems.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.